US 12,409,207 B2
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
David A. Sinclair, Cambridge, MA (US); and Yuancheng Lu, Cambridge, MA (US)
Assigned to President and Fellows of Harvard College, Cambridge, MA (US)
Filed by President and Fellows of Harvard College, Cambridge, MA (US)
Filed on May 16, 2023, as Appl. No. 18/318,566.
Application 18/318,566 is a continuation of application No. 17/280,384, previously published as PCT/US2019/053545, filed on Sep. 27, 2019.
Claims priority of provisional application 62/738,922, filed on Sep. 28, 2018.
Claims priority of provisional application 62/792,283, filed on Jan. 14, 2019.
Claims priority of provisional application 62/865,877, filed on Jun. 24, 2019.
Claims priority of provisional application 62/880,488, filed on Jul. 30, 2019.
Prior Publication US 2023/0338468 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 31/65 (2006.01); C12N 15/86 (2006.01)
CPC A61K 38/1709 (2013.01) [A61K 31/65 (2013.01); C12N 15/86 (2013.01); C12N 2750/14143 (2013.01)] 20 Claims
 
1. A syringe comprising a pharmaceutical composition, wherein the pharmaceutical composition comprises an expression vector comprising a polynucleotide encoding a human octamer-binding transcription factor 4 (OCT4) protein, a human sex determining region Y-box 2 (SOX2) protein, and a human Kruppel-like factor 4 (KLF4) protein, wherein the polynucleotide does not encode a Myc proto-oncogene (c-Myc) protein, wherein the polynucleotide does not encode a Nanog protein, wherein the polynucleotide is operably linked to at least one promoter, and wherein the pharmaceutical composition does not comprise a cytokine.